How to Choose a Leukopak Supplier: A Buyer’s Framework

Choosing a leukopak supplier comes down to seven criteria. Get these right and your starting material won’t be the variable that breaks your experiment or delays your IND.

Most scientists get to this decision with quotes in hand, a price comparison in a spreadsheet, and not much else. The criteria below are what actually differentiates one supplier from another: not marketing language, not catalog depth, but the specific things that determine whether your cells arrive ready to work.

The Seven Criteria

1. Cell Yield and Quality Specifications

A leukopak should come with published, contractually backed minimum specifications for total nucleated cell (TNC) count, granulocyte contamination, and hematocrit. Meaningful minimums for a standard leukapheresis product: at least 10 billion total nucleated cells per unit, granulocyte contamination below 3%, and hematocrit below 3%.

If a supplier can’t publish these numbers before you place an order, ask for the CoA template first. A supplier with consistent quality will share it without hesitation.

2. Donor Characterization Depth

The minimum you should receive with any leukopak: donor demographics (age, sex, race/ethnicity), HLA typing, infectious disease screening results, CMV serostatus, and immunophenotype data.

• HLA typing is table stakes for any allogeneic therapy program and required for HLA-restricted T cell assay design.
• CMV serostatus has real experimental consequences. CMV-seropositive donors have an expanded CMV-specific T cell population and phenotypically older T cells overall. If you’re running T cell expansion studies, knowing CMV status lets you control for it.
• Infectious disease screening is required for GMP and IND-enabling documentation per 21 CFR Part 1271.
• Immunophenotype data tells you what you’re starting with. If 40% of your PBMC fraction is monocytes and you’re running a T cell expansion protocol, you need to know that before you start.

3. HLA Typing Methodology

For most cell therapy research, you need high-resolution NGS typing across HLA-A, B, C, DRB1, DQB1, and DPB1 — a six-gene panel reported in G-code format. This provides allele-level data needed for HLA-restricted T cell assays, TCR studies, and allogeneic programs that need to identify HLA-homozygous donors. Serological typing misses homozygosity at the allele level.

4. Donor Recallability

A recallable donor pool means the supplier can bring back the same individual donor for additional collections when a client requests it. Critical for:

• Longitudinal studies — inter-donor variability swamps the biological signal. You need the same donor across timepoints.
• Process development (PD) — a recallable pool lets you lock in a donor and iterate on the process without conflating process variability with donor variability.
• Allogeneic programs — when a donor’s cells perform well in your assay, you need more of them.

Ask suppliers directly: “Is your donor pool recallable? Can I request the same donor ID for a new collection?”

5. The RUO-to-cGMP Path

Many suppliers maintain separate RUO and cGMP donor pools. When you transition to clinical manufacturing, you switch to different donors processed under different procedures — a material change requiring regulatory justification. The cleaner path: a supplier whose same characterized donor pool feeds both RUO and GMP production under the same SOPs. The distinction is the manufacturing controls applied downstream, not different cells from different donors.

6. Isolation Method and Cell Health

Positive selection uses beads that bind directly to target cells, cross-linking surface receptors and activating T cells before any intentional stimulation step. This reduces expansion potential and persistence in downstream manufacturing.

Negative selection removes unwanted cells without contacting target cells. T cells arrive unstimulated, with native surface phenotype intact, without the signaling events that push them toward exhaustion. For most cell therapy applications — CAR-T, CAR-NK, TCR engineering — negative isolation is the right starting point.

7. Documentation, Chain of Custody, and Audit Readiness

For any program with an IND in its future, FDA reviewers will want to see: CoA with specification ranges and actual lot results, Summary of Records for donor screening, chain of custody from collection through release, IRB-compliant donor consent records, and infectious disease screening per 21 CFR Part 1271. Evaluate documentation capabilities before you’ve built 18 months of process development data on a supplier.

The Buyer’s Checklist

How OrganaBio Approaches These Criteria

OrganaBio is a CTDMO (Cell and Gene Therapy Contract Testing, Development and Manufacturing Organization) based in Miami, Florida, operating its own HemaCenter apheresis facility and a 19,000 sq ft ISO 7 cGMP manufacturing facility.

• Donor characterization: Every unit ships with HLA typing, ID screening per 21 CFR 1271, CMV serostatus, immunophenotype, and donor demographics — standard, not optional.
• Donor recallability: The entire donor pool is recallable. Find a donor whose cells perform well; request that donor for additional collections.
• RUO-to-cGMP path: Same characterized donor pool and isolation procedures feed both RUO catalog products and cGMP manufacturing. The transition is a change in quality system, not a change in material source.
• Isolation method: All cell isolation uses negative selection. T cells, NK cells, B cells, and monocytes arrive unstimulated with native phenotype intact.
• Documentation: Full CoA, Summary of Records, chain of custody. 21 CFR Part 11 compliant QMS with IQ/OQ/PQ qualification, CAPA process, and full batch records.